Tech Company Financing Transactions
Neon Therapeutics Funding Round
On 12/6/2017, Neon Therapeutics raised $36 million in Series B funding from Access Industries, ArrowMark Partners and Casdin Capital.
Transaction Overview
Company Name
Announced On
12/6/2017
Transaction Type
Venture Equity
Amount
$36,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will support ongoing clinical development of Neon Therapeutics' lead product candidate, NEO-PV-01, a personal neoantigen vaccine, currently in Phase 1b development. Additionally, the funding will support the ongoing preclinical development of NEO-PTC-01, a personal neoantigen T cell program; and the company's NEON / SELECT approach focusing on shared neoantigen targets.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
40 Erie St. 110
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
We have assembled a team of world experts in cancer immunotherapy to develop therapies that target abnormal proteins called neoantigens, which are produced by cancer cells.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Cary Pfeffer
Chief Executive Officer
Hugh O'Dowd
Chief Financial Officer
Yasir Al-Wakeel
VP - Bus. Development
Robert Ang
VP - Human Resources
Teresa Regan
VP - Product Management
Kelledy Manson
VP - R & D
Richard Gaynor
Browse more venture capital transactions:
Prev: 12/6/2017: MyVR venture capital transaction
Next: 12/6/2017: Core10 venture capital transaction
Share this article
About Database of VC Transactions
We report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs